Introduction: The aim of our study was to estimate the prevalence of depression and to investigate its associated risk factors in patients with chronic renal failure on hemodialysis.

Methods: We conducted a descriptive cross-sectional study in the hemodialysis unit of the Division of Nephrology at the University Hospital of Sylvanus Olympio Lomé (Togo) from 1 January 2014 to 31 December 2014. Self-evaluation Scale as calibrated using the Beck Depression Inventory in his simplified version was our screening tool.

Results: During the study period, 88 patients were enrolled of whom 61.4% were men with a sex ratio of 1.6. The average age was 38.80 ± 13.24 years ranging from 12 to 66 years. The majority of patients (90.9%) were workers. Arterial hypertension was the most common somatic comorbidity (45.4%) recorded. Forty-six patients (52.3%) had hemodialysis duration between 1-4 years; 68.2% of patients had depression; 47.7% of depressed patients had severe depression. The occurrence of the depression is significantly related to the hemodialysis length (p= 0,008).

Conclusion: The management of chronic hemodialysis patient should be multidisciplinary including nephrologist and psychiatrist.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5268806PMC
http://dx.doi.org/10.11604/pamj.2016.25.26.9883DOI Listing

Publication Analysis

Top Keywords

patients chronic
8
chronic hemodialysis
8
sylvanus olympio
8
university hospital
8
patients
6
hemodialysis
5
depression
5
[depression patients
4
hemodialysis sylvanus
4
olympio university
4

Similar Publications

Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.

Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.

View Article and Find Full Text PDF

Background: Seizures in Alzheimer's Disease (AD) are increasingly recognized to occur and can increase cognitive decline and reduce survival compared to unaffected age-matched peers (Lyou et al. 2018). Administration of antiseizure medicines (ASMs) to AD patients with epileptiform activity may improve cognition (Vossel et al.

View Article and Find Full Text PDF

Background: Early-onset Alzheimer's disease (EOAD) associated with amyloid precursor protein (APP) duplications or presenilin (PSEN) variants increases risk of seizures. Targeting epileptiform activity with antiseizure medicine (ASM) administration to AD patients may beneficially attenuate cognitive decline (Vossel et al, JAMA Neurology 2021). However, whether mechanistically distinct ASMs differentially suppress seizures in discrete EOAD models is understudied (Lehmann et al, Neurochem Res 2021).

View Article and Find Full Text PDF

Background: There are no cures for Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by elevation of beta-amyloid and tau proteins besides neuronal death and causing cognitive impairment. Phosphodiesterase 5 (PDE5) is a cyclic guanosine monophosphate-degrading enzyme involved in numerous biological pathways including those relevant to memory formation. PDE5 inhibition offers the potential to attenuate AD progression by acting at the downstream level of beta-amyloid and tau elevation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!